SAN FRANCISCO (EGMN) - A revolutionary new staging system for lung cancer will profoundly impact treatment decisions and patients' eligibility for clinical trials, even as it unites clinicians from disparate specialties and nations in characterizing tumor characteristics, node involvement, and metastasis.Fully one in six lung cancer patients will receive a different staging category based on the just-released 7th edition of the TNM staging system, reported Dr. Peter Goldstraw, chair of the staging...